What extrusion parameters control knot-pull tensile retention in PLG 8537 monofilament sutures?

PURASORB PLG 8537, a medical-grade poly(L-lactide-co-glycolide) with a lactide:glycolide ratio of 85:15 and nominal inherent viscosity of 3.7 dL/g, is converted into absorbable monofilament sutures through a single-screw extrusion and multi-stage hot drawing sequence. Pre-drying is performed in a vacuum oven at 60°C and 0.1 mbar for 12 h; residual moisture after drying is verified by Karl Fischer titration according to USP 921 Method Ic at ≤ 0.01% w/w. Moisture levels above 0.02% w/w during melt processing promote hydrolytic chain scission, measurable as a reduction in inherent viscosity and a corresponding loss in suture tensile retention. Extrusion is performed on a single-screw extruder with a 24:1 L/D ratio and a 3:1 compression ratio screw. Barrel temperature zones are set at 185°C, 205°C, 215°C, and 215°C; the die temperature is controlled at 210°C ± 5°C. Melt temperature at the die exit is held below 225°C to avoid lactide formation. A melt pump between the screw tip and die stabilizes output at 0.4 kg/h to 0.8 kg/h while suppressing pressure variations that cause diameter fluctuation. The molten filament is quenched in a water bath at 25°C to 30°C and then drawn at 70°C to 90°C with a total draw ratio of 8:1 to 10:1. Annealing follows at 110°C under vacuum for 4 h to reduce residual stresses and stabilize crystalline structure. Suture diameters from 0.2 mm to 0.5 mm are drawn to USP 861 tolerance classes; knot-pull tensile strength is evaluated with a square knot and straight tensile strength per United States Pharmacopeia 881. Degradation testing is conducted in phosphate-buffered saline at 37°C according to ASTM F1635, with mass loss and molar mass monitored until mechanical failure. Compliance for implant use requires ISO 10993-5 cytotoxicity, ISO 10993-10 sensitization, and sterility assurance level of 10⁻⁶ per USP 71.

Process limitations in monofilament melt spinning of high-inherent-viscosity PLG 8537 arise primarily from shear heating at high screw speeds and from moisture-induced hydrolysis. Screw speeds above 30 rpm with a 24:1 L/D screw generate melt temperatures above 225°C even when barrel set points remain lower, producing lactide monomer and causing filament brittleness. Draw resonance below a 7:1 draw ratio leads to unacceptable diameter variation above ±0.01 mm, while draw ratios above 11:1 cause fibrillation at the suture surface. The material should not be combined with amine-based processing aids; residual amines accelerate ester cleavage at melt temperatures.

Injection molding of PLG 8537 into interference screws for anterior cruciate ligament fixation is conducted on a hydraulic injection molding machine with clamp force between 300 kN and 800 kN, using a reciprocating screw with 20:1 L/D and a low-compression metering profile. Pellets are dried in a desiccant dryer at 60°C for 12 h with a dew point of -40°C, achieving residual moisture ≤ 0.01% w/w. Barrel zones are profiled at 190°C, 210°C, 230°C, and 235°C; nozzle temperature is held at 230°C ± 5°C. Mold temperature is controlled at 30°C to 40°C. Because the high molar mass of PLG 8537 produces low melt flow as determined by ISO 1133-1:2022, filling thin-walled screw threads requires injection pressures between 120 MPa and 180 MPa and injection speeds of 20 mm/s to 50 mm/s. Holding pressure is set at 70 MPa to 90 MPa for 5 s to 10 s, and cooling time is 30 s to 60 s depending on wall thickness. Gate diameters below 1.2 mm create shear rates above 10,000 s⁻¹, which induced localized molar mass reduction and visible darkening in production trials; therefore gate dimensions for PLG 8537 are maintained at 1.5 mm to 2.0 mm, and runner diameters are specified at 4 mm minimum. After molding, interference screws are annealed at 120°C under vacuum for 4 h to reduce residual stress and stabilize the geometry for terminal sterilization. Dimensional verification follows ISO 13781 for poly(lactide) implants. Tensile and flexural properties are tested on molded coupons per ASTM D638-14 Type V and ISO 178. In vitro degradation uses ASTM F1635. The molded device is tested for cytotoxicity per ISO 10993-5, implantation per ISO 10993-6, and endotoxin per USP 85. Published data for this specific configuration is limited regarding long-term in vivo load retention; device validation therefore requires a 12-month ovine implantation study with interim mechanical and histology endpoints.

Fused granulate deposition of PLG 8537 for load-bearing cancellous bone scaffolds

PLG 8537 is processed into patient-specific scaffolds by fused granulate deposition, in which dried polymer granules are fed into a heated micro-extruder mounted on a three-axis motion system. Drying is carried out at 60°C for 12 h under vacuum; granules are then transferred under dry nitrogen to the feedstock hopper. The micro-extruder uses a 0.4 mm nozzle, a barrel temperature of 210°C ± 5°C, and a chamber temperature of 35°C to 45°C to reduce warpage. Layer height is set at 0.2 mm, print speed between 15 mm/s and 25 mm/s, and extrusion multiplier between 0.95 and 1.05. Scaffold architectures with pore sizes from 600 µm to 1200 µm and porosity from 50% to 70% are generated by orthogonal strut deposition. Residual stress accumulates at the interface between the printed part and a cold build plate, producing delamination at strut junctions when chamber temperature falls below 30°C. Annealing after printing at 110°C for 4 h under vacuum reduces dimensional distortion and improves interlayer adhesion. Compressive mechanical properties are measured by ASTM D1621-16 for cellular plastics. In vitro cytocompatibility uses ISO 10993-5; in vivo bone response uses ISO 10993-6 implantation. The high molecular weight of PLG 8537 maintains strut stiffness during the first 8 to 12 weeks of hydrolysis; published data for this specific configuration is limited, so implant validation must include micro-CT evaluation of bone ingrowth at 4, 12, and 26 weeks.

A 4% w/v solution of PLG 8537 in dichloromethane is applied to solvent-cast periodontal barrier membranes using a knife coater with gap settings from 250 µm to 500 µm on a polished stainless steel release liner. The solution is prepared under a nitrogen atmosphere to prevent moisture uptake; the polymer is dissolved at 25°C over 12 h with continuous stirring at 200 rpm. Cast film is dried in a two-stage oven at 25°C for 6 h followed by 60°C under vacuum for 8 h, reducing residual solvent to the limits shown below. Membrane thickness after drying ranges from 150 µm to 300 µm; thickness uniformity is verified by contact micrometer with a variation below ±10%. The membrane is used as a resorbable barrier in guided bone regeneration to prevent epithelial migration into osseous defects. Tensile properties are evaluated according to ASTM D882-18 at 23°C and 50% RH, and suture pull-out resistance is measured by a validated benchtop method using a 4-0 polyglycolide suture. In vitro degradation is followed by ASTM F1635 in phosphate-buffered saline at 37°C. Cytotoxicity testing is performed per ISO 10993-5, implantation per ISO 10993-6, and residual solvents per USP 467.

When compression molding replaces thermoforming in PLG 8537 craniomaxillofacial mesh fabrication

Compression molding is selected over melt extrusion and thermoforming for PLG 8537 craniomaxillofacial mesh when fiber reinforcement or multi-layer laminates are required. Dried pellets are placed between two PTFE-coated steel platens and heated to 220°C ± 5°C under 1 MPa to 3 MPa for 3 min, then pressed at 15 MPa to 25 MPa for 5 min and cooled at 10°C/min to 60°C before demolding. The resulting sheet with thickness between 0.5 mm and 1.5 mm is then laser-cut into mesh patterns with strut widths of 0.8 mm to 1.2 mm. Compression molding avoids the shear-induced degradation observed in twin-screw extrusion at screw speeds above 100 rpm, but it introduces anisotropic residual stresses if cooling is non-uniform. Annealing at 120°C for 4 h under vacuum is required before terminal cleaning and double-blister packaging. Flexural modulus and strength are measured by ISO 178; in vitro degradation is followed by ASTM F1635. The device is evaluated for cytotoxicity per ISO 10993-5, genotoxicity per ISO 10993-3, and subchronic systemic toxicity per ISO 10993-11. Sterilization by ethylene oxide requires aeration at 45°C for 12 h to reduce ethylene oxide residuals below the limits of ISO 10993-7; gamma irradiation is not recommended because the high molecular weight backbone undergoes chain scission and embrittlement at doses above 25 kGy.

Nerve conduits from PLG 8537 are produced by melt extrusion through an annular die with a 2 mm outer diameter and 0.2 mm wall thickness, followed by vacuum sizing in a water bath at 25°C. Drying before extrusion uses a vacuum oven at 60°C for 12 h. The extruder barrel is set at 190°C to 230°C, die temperature at 220°C, and screw speed at 10 rpm to 20 rpm. A nitrogen purge on the feed throat prevents moisture absorption during processing. The conduit is cut into 10 mm to 20 mm lengths and annealed at 110°C for 4 h. Wall-thickness variation above ±0.05 mm at the annular die leads to collapse under vacuum sizing; therefore die alignment and melt temperature uniformity are verified before each production run. Permeability is measured by a pressure decay method at 0.2 bar, and suture retention is measured using a 7-0 monofilament polypropylene suture. Cytotoxicity is evaluated by ISO 10993-5, and local tissue reaction by ISO 10993-6 after intramuscular implantation. Degradation kinetics are monitored in phosphate-buffered saline at 37°C per ASTM F1635, with residual molar mass and mass loss recorded at 30, 60, 90, and 180 days. Published data for this specific configuration is limited regarding axonal regeneration rates, so functional recovery must be confirmed in a rat sciatic nerve gap model with histomorphometry at 12 weeks.